- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Emeryville Today
By the People, for the People
Rhenman & Partners Asset Management Boosts Stake in Dynavax Technologies
The investment firm increased its position in the biopharmaceutical company by over 36% in the third quarter.
Published on Mar. 8, 2026
Got story updates? Submit your updates here. ›
Rhenman & Partners Asset Management AB lifted its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 36.6% in the third quarter, according to the company's SEC filing. The firm now owns 772,000 shares of the biopharmaceutical company's stock, worth approximately $7.7 million.
Why it matters
Dynavax Technologies is a biopharmaceutical company focused on developing novel vaccines and immunotherapies. The increase in Rhenman & Partners' stake suggests the investment firm sees growth potential in Dynavax's pipeline, which includes candidates targeting hepatitis B, influenza, respiratory syncytial virus, and other infectious diseases.
The details
Rhenman & Partners Asset Management added 207,000 shares of Dynavax to its portfolio during the third quarter. The firm now owns approximately 0.66% of the biopharmaceutical company. Other notable institutional investors that have stakes in Dynavax include GW&K Investment Management, Rafferty Asset Management, and Choreo LLC.
- Rhenman & Partners Asset Management increased its Dynavax stake in the third quarter of 2025.
The players
Rhenman & Partners Asset Management AB
A Swedish investment management firm that has increased its stake in Dynavax Technologies Corporation.
Dynavax Technologies Corporation
A biopharmaceutical company focused on developing novel vaccines and immunotherapies, including candidates targeting hepatitis B, influenza, and respiratory syncytial virus.
The takeaway
Rhenman & Partners' increased investment in Dynavax suggests the firm sees strong growth potential in the biopharmaceutical company's pipeline of innovative vaccine and immunotherapy candidates, which could signal positive developments for Dynavax in the coming quarters.
